(Q33929461)

30 July 2017

1 reference

title

Development of target-based antineoplastic agents (English)

1 reference

30 July 2017

Stadler WM

1

1 reference

30 July 2017

Ratain MJ

series ordinal

2

1 reference

30 July 2017

publication date

1 February 2000

1 reference

Investigational New Drugs

30 July 2017

published in

1 reference

30 July 2017

volume

18

1 reference

30 July 2017

issue

1

1 reference

30 July 2017

page(s)

7-16

1 reference

Tacrolimus oral bioavailability doubles with coadministration of ketoconazole

30 July 2017

cites work

1 reference

12 December 2020

Results and validation of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine

1 reference

12 December 2020

There are no bad anticancer agents, only bad clinical trial designs--twenty-first Richard and Hinda Rosenthal Foundation Award Lecture

1 reference

12 December 2020

Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients

1 reference

12 December 2020

Oral chemotherapy: rationale and future directions

1 reference

12 December 2020

Pharmacokinetic and toxicity scaling of the antitumor agents amsacrine and CI-921, a new analogue, in mice, rats, rabbits, dogs, and humans.

1 reference

12 December 2020

Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth

1 reference

12 December 2020

Antiangiogenesis for cancer therapy

1 reference

12 December 2020

Is the control of disease progression within our grasp? Review of the GRISAR study. (Gruppo Reumatologi Italiani Studio Artrite Reumatoide).

1 reference

12 December 2020

Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents

1 reference

12 December 2020

Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. The Cooperative Systematic Studies of Rheumatic Diseases Group

1 reference

12 December 2020

Phase I and II trials of novel anti-cancer agents: endpoints, efficacy and existentialism. The Michel Clavel Lecture, held at the 10th NCI-EORTC Conference on New Drugs in Cancer Therapy, Amsterdam, 16-19 June 1998.

1 reference

12 December 2020

Clinical investigation of a cytostatic calcium influx inhibitor in patients with refractory cancers

1 reference

12 December 2020

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

1 reference

12 December 2020

Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice

1 reference

12 December 2020

Matrix metalloproteinase inhibitors: present achievements and future prospects

1 reference

12 December 2020

Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies.

1 reference

12 December 2020

Inhibitors of cyclin-dependent kinase and cancer

1 reference

12 December 2020

Ketoconazole to reduce the need for cyclosporine after cardiac transplantation

1 reference

12 December 2020

The 'natural' history of active rheumatoid arthritis over 3-6 months--an analysis of patients enrolled into trials of potential disease-modifying anti-rheumatic drugs, and treated with placebo.

1 reference

12 December 2020

Results of single and repeat dose studies of the oral matrix metalloproteinase inhibitor marimastat in healthy male volunteers

1 reference

12 December 2020

The Effect of Glucocorticoids on Joint Destruction in Rheumatoid Arthritis

1 reference

12 December 2020

Advances in the development of farnesyltransferase inhibitors: substrate recognition by protein farnesyltransferase.

1 reference

12 December 2020

A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group

1 reference

12 December 2020

Randomized discontinuation trials: Utility and efficiency

1 reference

12 December 2020

New phase I trial methodology

1 reference

12 December 2020

Identifiers

DOI

10.1023/A:1006371512390

1 reference

Dimensions Publication ID

30 July 2017

1020005488

0 references

1 reference